Literature DB >> 16539397

Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.

Yoshiaki Isobe1, Ayumu Kurimoto, Masanori Tobe, Kazuki Hashimoto, Tomoaki Nakamura, Kei Norimura, Haruhisa Ogita, Haruo Takaku.   

Abstract

Recently we reported the adenine derivatives 3a-d as novel interferon (IFN) inducers. In the present study, we conducted a detailed structure-activity relationship study of analogues of 3a-d with respect to their IFN-inducing activity, mainly focusing on the N(9)-position of the adenine. From this study, we found that introduction of the 3-pyridylmethyl moiety was effective to increase in vitro activity, and compound 9ae was identified as being the most potent IFN inducer. This compound gave a minimum effective concentration (MEC) of 3 nM, which is comparable with that of R-848, a second generation IFN inducer. Compound 9ae also demonstrated potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice. Furthermore, compound 9ae induced IFN in monkeys in a dose dependent manner, with a potency superior to that of R-848. In addition, 9ae did not cause emesis in ferrets even at a dose of 30 mg/kg. In this study the maximum plasma concentration of 9ae was 1019 ng/mL (ca. 3.1 microM), which was approximately 1000-fold higher than the MEC value. Therefore, with respect to both the efficacy and the safety margin, compound 9ae (SM-276001) is considered to be a promising compound as an orally active IFN inducer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16539397     DOI: 10.1021/jm051089s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands as Self-Adjuvanting Immunopotentiators.

Authors:  Dong Gao; Yu Liu; Yuwen Diao; Ningning Gao; Zhulin Wang; Wenqi Jiang; Guangyi Jin
Journal:  ACS Med Chem Lett       Date:  2015-01-30       Impact factor: 4.345

2.  Novel drugs targeting Toll-like receptors for antiviral therapy.

Authors:  Mira C Patel; Kari Ann Shirey; Lioubov M Pletneva; Marina S Boukhvalova; Alfredo Garzino-Demo; Stefanie N Vogel; Jorge Cg Blanco
Journal:  Future Virol       Date:  2014-09       Impact factor: 1.831

3.  Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.

Authors:  Neil Benson; Joost de Jongh; Jonathan D Duckworth; Hannah M Jones; Henry E Pertinez; Jaiessh K Rawal; Tamara J van Steeg; Piet H Van der Graaf
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

4.  Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.

Authors:  Hélène G Bazin; Yufeng Li; Juhienah K Khalaf; Sandra Mwakwari; Mark T Livesay; Jay T Evans; David A Johnson
Journal:  Bioorg Med Chem Lett       Date:  2015-01-31       Impact factor: 2.823

Review 5.  Opportunities for the replacement of animals in the study of nausea and vomiting.

Authors:  A M Holmes; J A Rudd; F D Tattersall; Q Aziz; P L R Andrews
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

6.  Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series.

Authors:  Jay T Evans; Laura S Bess; Sandra C Mwakwari; Mark T Livesay; Yufeng Li; Van Cybulski; David A Johnson; Hélène G Bazin
Journal:  ACS Omega       Date:  2019-09-10

7.  Distinct trans-placental effects of maternal immune activation by TLR3 and TLR7 agonists: implications for schizophrenia risk.

Authors:  Jonathan Cavanagh; Brian J Morris; Jaedeok Kwon; Maria Suessmilch; Alison McColl
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

Review 8.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

Review 9.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.